Wells Fargo Upgrades Achillion Pharmaceuticals (ACHN) to Outperform
Tweet
Share
E-mailGet Alerts ACHN Hot Sheet
Price: $0.79 --0%
Rating Summary:
11 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 9 | New: 9
Rating Summary:
11 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 9 | New: 9
Join SI Premium – FREE
Wells Fargo upgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Market Perform to Outperform with a price target of $11-$13 (from $7-$8). Analyst Brian Abrahams is more confident as ACH-3422 progresses without incident, and he is optimistic on readouts for 3422 and 3102.
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $7.36 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Akamai Technologies (AKAM) to Neutral 'on Account of Confidence in Revenue Reacceleration'
- ICICI Securities Downgrades Landmark Cars (LANDMARK:IN) to Add (2)
- Cantor Fitzgerald Downgrades Better Home & Finance Holding (BETR) to Neutral
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT Change, Hot Upgrades, UpgradesRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
